RedHill Biopharma (RDHL) Divestments (2016 - 2022)

RedHill Biopharma has reported Divestments over the past 10 years, most recently at -$22000.0 for Q3 2022.

  • Quarterly Divestments rose 99.74% to -$22000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2022, up 201.99% year-over-year, with the annual reading at $1.7 million for FY2025, 18888.89% up from the prior year.
  • Divestments was -$22000.0 for Q3 2022 at RedHill Biopharma, up from -$163000.0 in the prior quarter.
  • Over five years, Divestments peaked at $11.7 million in Q3 2019 and troughed at -$8.5 million in Q3 2021.
  • The 5-year median for Divestments is $573500.0 (2018), against an average of $1.3 million.
  • Year-over-year, Divestments plummeted 2897.71% in 2019 and then skyrocketed 2093.02% in 2022.
  • A 5-year view of Divestments shows it stood at $175000.0 in 2018, then plummeted by 2897.71% to -$4.9 million in 2019, then skyrocketed by 260.36% to $7.9 million in 2020, then crashed by 55.46% to $3.5 million in 2021, then tumbled by 100.63% to -$22000.0 in 2022.
  • Per Business Quant, the three most recent readings for RDHL's Divestments are -$22000.0 (Q3 2022), -$163000.0 (Q2 2022), and $8.5 million (Q1 2022).